---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-010308"
form_type: "8-K"
ticker: "CELC"
cik: "0001603454"
company_name: "Celcuity Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T08:47:44.643176+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Celcuity reports Q1 net loss $37.0M; VIKTORIA-1 WT data expected Q3 2025

## Summary
- Net loss of $37.0M ($0.86/sh) vs $21.6M ($0.64/sh) in Q1 2024; non-GAAP adj. net loss $34.7M ($0.81/sh).
- Cash, cash equivalents and investments of ~$206M at March 31, 2025, expected to fund operations through 2026.
- VIKTORIA-1 PIK3CA wild-type cohort topline data now anticipated in Q3 2025; mutant cohort data in Q4 2025.
- VIKTORIA-2 Phase 3 first patient dosing on track for Q2 2025; CELC-G-201 Phase 1b data expected late Q2 2025.
- Clinical trial collaboration initiated with Dana Farber and Mass General for gedatolisib in endometrial cancer.

## SEC filing metadata
- accession: 0001641172-25-010308
- form_type: 8-K
- ticker: CELC
- cik: 0001603454
- company_name: Celcuity Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1603454/000164117225010308/0001641172-25-010308-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1603454/000164117225010308/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-010308
- JSON: https://secwatch.observer/filing/0001641172-25-010308.json
- Plain text: https://secwatch.observer/filing/0001641172-25-010308.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.